Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine + CAG in newly diagnosed unfit AML
NCT04254640Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cladribine in acute myeloid leukemia (AML), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04254640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04254640.